NCT05398718

Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

Bi-directional Real-world Cohort Study on Sotrovimab and Its Impact on the Strength and Duration of the Immune Response to Natural SARS-CoV-2 Infection in Real-life Setting in the UAE and the Kingdom of Bahrain

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 20,000 (estimated)
• Sponsor: Abu Dhabi Health Services Company · Other Government
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vaccine pivotal studies supported by the authorities' willingness to expedite understanding of the role of monoclonal antibodies such as sotrovimab in the management of COVID-19 and expertise to integrate the latest knowledge into the local or regional COVID-19 management guidelines. The aim of this study is to collect local clinical evidence for sotrovimab effect in the real-life setting in the UAE and the Kingdom of Bahrain. Overall study population is 20,000 and the duration of the study will be approximately six months from recruitment date.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Sotrovimab	collect local clinical evidence for sotrovimab effect in the real-life setting

Timeline

• Start date: 2022-05-12
• Primary completion: 2022-12-15
• Completion: 2022-12-31
• First posted: 2022-06-01
• Last updated: 2022-06-01

Locations

1 site across 1 country: Bahrain